Argos Therapeutics (ARGS) Shares Gap Up to $0.17

Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) gapped up before the market opened on Monday . The stock had previously closed at $0.17, but opened at $0.17. Argos Therapeutics shares last traded at $0.18, with a volume of 4023037 shares traded.

Separately, Zacks Investment Research cut shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating and three have issued a hold rating to the stock. Argos Therapeutics presently has an average rating of “Hold” and an average price target of $4.13.

The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new position in shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Argos Therapeutics (ARGS) Shares Gap Up to $0.17” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply